Search

Copyright of Pediatric Endocrinology, Diabetes & Metabolism is the property of Termedia Publishing House and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Pediatric Endocrinology, Diabetes & Metabolism is the property of Termedia Publishing House and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

23 consecutive patients were enrolled in the study, 21 after deep venous thrombosis, in 40% complicated by pulmonary embolism, and 2 with mechanical prosthetic heart valves with contraindications to oral anticoagulation. All of them received fraxiparine s.c. in doses of 7500 U anti-Xa daily, from at least 9 to 24 months. Fraxiparine was well tolerated. Re-thrombosis or signs of pulmonary embolisation as well as bleeding complications have not been observed. Long-term subcutaneous administration of fraxiparine is an effective and safe alternative for the prophylaxis of thromboembolism in cases with contraindication to oral anticoagulation, although the danger of osteoporosis should be considered.